Selecting valid in vitro biocompatibility tests that predict the in vivo healing response of synthetic vascular prostheses.
We have investigated the usefulness of six in vitro biocompatibility tests in predicting the healing performance of polyester vascular prostheses as observed in previous canine in vivo trials. Vascular grafts were evaluated by using (i) a direct contact (DC) assay, (ii) an extract dilution (ED) assay on murine fibroblast cells, (iii) a DC assay on endothelial cells, (iv) a complement activation study, (v) a leucocyte activation study of CD18 integrin subunit expression on human polymorphonuclear cells (PMNs) and (vi) interleukin-2 receptor expression on lymphocytes. Uncleaned polyester grafts had previously been associated with poor healing and gelatin-impregnated polyester grafts with delayed but satisfactory healing, whereas commercially cleaned polyester grafts had demonstrated excellent healing. Lightweight and heavyweight knitted and woven polyester grafts supplied specifically for this project were studied, each with a different surface condition, i.e. commercially available (CP), uncleaned (UP) and impregnated with gelatin (GP). The UP grafts induced fibroblast cytotoxicity according to the ED assay, poor migration and viability of endothelial cells, and an elevated expression of CD18 and interleukin-2 receptor on PMNs and lymphocytes, respectively. In contrast, the CP grafts promoted good endothelial cell growth, no evidence of cytotoxicity and a weaker cell activation, and the GP grafts were found to be non-cytotoxic, to exhibit a good cellular response and to moderate cell activation. The complement activation assay and the DC assay on fibroblasts were found to be less useful and less discriminating. From this, it is concluded that the two cell activation measurements, the DC assay on endothelial cells and ED assay on fibroblasts, are useful in predicting the in vivo healing response of arterial polyester substitutes.
Marois
Y
Y
Department of Surgery, Laval University, Québec City, Canada.
Guidoin
R
R
Roy
R
R
Vidovsky
T
T
Jakubiec
B
B
Sigot-Luizard
M F
MF
Braybrook
J
J
Mehri
Y
Y
Laroche
G
G
King
M
M
D000704:Analysis of Variance; D000818:Animals; D001672:Biocompatible Materials; D001807:Blood Vessel Prosthesis / Q000592:standards*; D018821:CD18 Antigens / Q000096:biosynthesis / Q000276:immunology; D002470:Cell Survival / Q000502:physiology; D002478:Cells, Cultured; D003167:Complement Activation; D004730:Endothelium, Vascular / Q000166:cytology / Q000502:physiology; D005347:Fibroblasts / Q000166:cytology / Q000187:drug effects; D005780:Gelatin / Q000737:chemistry; D006801:Humans; D008213:Lymphocyte Activation / Q000276:immunology / Q000502:physiology; D051379:Mice; D009504:Neutrophils / Q000166:cytology / Q000276:immunology / Q000378:metabolism; D011091:Polyesters / Q000378:metabolism / Q000633:toxicity; D015375:Receptors, Interleukin-2 / Q000378:metabolism; D017550:Spectroscopy, Fourier Transform Infrared; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology / Q000378:metabolism; D014945:Wound Healing / Q000276:immunology / Q000502:physiology
D001672:Biocompatible Materials; D018821:CD18 Antigens; D011091:Polyesters; D015375:Receptors, Interleukin-2; D005780:Gelatin